Huifeng Yun

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Jeffrey R. Curtis, Fenglong Xie, Huifeng Yun et al. · Annals of the Rheumatic Diseases · 2016 · 277 citations · Full text

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen et al. · Annals of the Rheumatic Diseases · 2020 · 214 citations · Full text

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

Huifeng Yun, Shuo Yang, Lang Chen et al. · Arthritis & Rheumatology · 2016 · 211 citations · Full text

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer

Frank I. Scott, Ronac Mamtani, Colleen Brensinger et al. · JAMA Dermatology · 2015 · 171 citations · Full text

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

Fenglong Xie, Huifeng Yun, Sasha Bernatsky et al. · Arthritis & Rheumatology · 2016 · 171 citations · Full text